secwatch.observer — SEC 8-K summary
======================================

Issuer:     Calidi Biotherapeutics, Inc. (CLDI)
CIK:        0001855485
Form:       8-K
Filed at:   2023-10-27T23:59:59+00:00
Accession:  0001493152-23-038547
Event type: leadership
Sentiment:  negative
Materiality: 0.65
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Calidi Biotherapeutics CAO/Interim CFO Tony Kalajian resigns
------------------------------------------------------------

- Tony Kalajian resigned all positions on October 23, 2023.
- He served as Chief Accounting Officer and interim Chief Financial Officer.
- No replacement or interim successor has been announced.
- No reason for resignation was disclosed in the filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1855485/000149315223038547/0001493152-23-038547-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1855485/000149315223038547/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-038547

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer